The Filings Report

ResMed Inc.

RMDNYSECIK 943819Healthcare / Medical Devicesfiscal year ends June68 quarters since 2009

Revenue, Q4 FY2026
$1.5B
+8.6% on Q4 FY2025
Net income
$383M
+1.0% on Q4 FY2025
Free cash flow
$404M
−20.6% on Q4 FY2025
Diluted EPS
—
not filed for a derived quarter
Revenue, TTM
$5.7B
trailing four quarters
Net margin, TTM
26.9%
net income $1.5B
Free cash flow, TTM
$1.6B
$1.8B less $156M capex
Cash and equivalents
$1.5B
long-term debt $399M, Jun 30, 2026
Shares, 12-month change
−1.5%
144M shares, Jun 30, 2026
Buybacks, TTM
$700M
2.1% of market value
Dividends, TTM
$350M
1.1% of market value
Market value
$33.2B
at the close, buybacks

Latest quarter Q4 FY2026, filed August 13, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q4 FY2026, the quarter ended June 30, 2026, ResMed Inc. reported revenue of $1.5B, +8.6% on Q4 FY2025, and net income of $383M (+1.0%). Operating margin was 30.7%. Free cash flow, operating cash flow less capital expenditures, was $404M ($455M less $51M). The income statement for this quarter is derived from the annual filing, so no per-share figure is shown; per-share values are never computed by subtraction.

The last 16 quarters

Q1 FY2023 to Q4 FY2026, through the filing of August 13, 2026.

Revenue and net incomeRevenueNet income
$0$500M$1.0B$1.5BQ1'23, Revenue: $950MQ1'23, Net income: $210MQ1'23Q2'23, Revenue: $1.0BQ2'23, Net income: $225MQ2'23Q3'23, Revenue: $1.1BQ3'23, Net income: $233MQ3'23Q4'23, Revenue: $1.1BQ4'23, Net income: $230MQ4'23Q1'24, Revenue: $1.1BQ1'24, Net income: $219MQ1'24Q2'24, Revenue: $1.2BQ2'24, Net income: $209MQ2'24Q3'24, Revenue: $1.2BQ3'24, Net income: $300MQ3'24Q4'24, Revenue: $1.2BQ4'24, Net income: $292MQ4'24Q1'25, Revenue: $1.2BQ1'25, Net income: $311MQ1'25Q2'25, Revenue: $1.3BQ2'25, Net income: $345MQ2'25Q3'25, Revenue: $1.3BQ3'25, Net income: $365MQ3'25Q4'25, Revenue: $1.3BQ4'25, Net income: $380MQ4'25Q1'26, Revenue: $1.3BQ1'26, Net income: $349MQ1'26Q2'26, Revenue: $1.4BQ2'26, Net income: $393MQ2'26Q3'26, Revenue: $1.4BQ3'26, Net income: $399MQ3'26Q4'26, Revenue: $1.5BQ4'26, Net income: $383MQ4'26$0$500M$1.0B$1.5BQ1'23, Revenue: $950MQ1'23, Net income: $210MQ2'23, Revenue: $1.0BQ2'23, Net income: $225MQ2'23Q3'23, Revenue: $1.1BQ3'23, Net income: $233MQ4'23, Revenue: $1.1BQ4'23, Net income: $230MQ4'23Q1'24, Revenue: $1.1BQ1'24, Net income: $219MQ2'24, Revenue: $1.2BQ2'24, Net income: $209MQ2'24Q3'24, Revenue: $1.2BQ3'24, Net income: $300MQ4'24, Revenue: $1.2BQ4'24, Net income: $292MQ4'24Q1'25, Revenue: $1.2BQ1'25, Net income: $311MQ2'25, Revenue: $1.3BQ2'25, Net income: $345MQ2'25Q3'25, Revenue: $1.3BQ3'25, Net income: $365MQ4'25, Revenue: $1.3BQ4'25, Net income: $380MQ4'25Q1'26, Revenue: $1.3BQ1'26, Net income: $349MQ2'26, Revenue: $1.4BQ2'26, Net income: $393MQ2'26Q3'26, Revenue: $1.4BQ3'26, Net income: $399MQ4'26, Revenue: $1.5BQ4'26, Net income: $383MQ4'26

Net income losses drawn in red.

Free cash flow
$0$200M$400M$600MQ1'23, Free cash flow: $16MQ1'23Q2'23, Free cash flow: $101MQ2'23Q3'23, Free cash flow: $254MQ3'23Q4'23, Free cash flow: $203MQ4'23Q1'24, Free cash flow: $256MQ1'24Q2'24, Free cash flow: $249MQ2'24Q3'24, Free cash flow: $381MQ3'24Q4'24, Free cash flow: $415MQ4'24Q1'25, Free cash flow: $308MQ1'25Q2'25, Free cash flow: $288MQ2'25Q3'25, Free cash flow: $558MQ3'25Q4'25, Free cash flow: $508MQ4'25Q1'26, Free cash flow: $414MQ1'26Q2'26, Free cash flow: $311MQ2'26Q3'26, Free cash flow: $520MQ3'26Q4'26, Free cash flow: $404MQ4'26$0$200M$400M$600MQ1'23, Free cash flow: $16MQ2'23, Free cash flow: $101MQ2'23Q3'23, Free cash flow: $254MQ4'23, Free cash flow: $203MQ4'23Q1'24, Free cash flow: $256MQ2'24, Free cash flow: $249MQ2'24Q3'24, Free cash flow: $381MQ4'24, Free cash flow: $415MQ4'24Q1'25, Free cash flow: $308MQ2'25, Free cash flow: $288MQ2'25Q3'25, Free cash flow: $558MQ4'25, Free cash flow: $508MQ4'25Q1'26, Free cash flow: $414MQ2'26, Free cash flow: $311MQ2'26Q3'26, Free cash flow: $520MQ4'26, Free cash flow: $404MQ4'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$500M$1.0B$1.5B$2.0BQ1'23, Cash and equivalents: $207MQ1'23, Long-term debt: $785MQ1'23Q2'23, Cash and equivalents: $253MQ2'23, Long-term debt: $1.8BQ2'23Q3'23, Cash and equivalents: $228MQ3'23, Long-term debt: $1.6BQ3'23Q4'23, Cash and equivalents: $228MQ4'23, Long-term debt: $1.4BQ4'23Q1'24, Cash and equivalents: $209MQ1'24, Long-term debt: $1.4BQ1'24Q2'24, Cash and equivalents: $210MQ2'24, Long-term debt: $1.2BQ2'24Q3'24, Cash and equivalents: $238MQ3'24, Long-term debt: $997MQ3'24Q4'24, Cash and equivalents: $238MQ4'24, Long-term debt: $697MQ4'24Q1'25, Cash and equivalents: $426MQ1'25, Long-term debt: $668MQ1'25Q2'25, Cash and equivalents: $522MQ2'25, Long-term debt: $663MQ2'25Q3'25, Cash and equivalents: $933MQ3'25, Long-term debt: $663MQ3'25Q4'25, Cash and equivalents: $1.2BQ4'25, Long-term debt: $658MQ4'25Q1'26, Cash and equivalents: $1.4BQ1'26, Long-term debt: $409MQ1'26Q2'26, Cash and equivalents: $1.4BQ2'26, Long-term debt: $404MQ2'26Q3'26, Cash and equivalents: $1.7BQ3'26, Long-term debt: $404MQ3'26Q4'26, Cash and equivalents: $1.5BQ4'26, Long-term debt: $399MQ4'26$0$500M$1.0B$1.5B$2.0BQ1'23, Cash and equivalents: $207MQ1'23, Long-term debt: $785MQ2'23, Cash and equivalents: $253MQ2'23, Long-term debt: $1.8BQ2'23Q3'23, Cash and equivalents: $228MQ3'23, Long-term debt: $1.6BQ4'23, Cash and equivalents: $228MQ4'23, Long-term debt: $1.4BQ4'23Q1'24, Cash and equivalents: $209MQ1'24, Long-term debt: $1.4BQ2'24, Cash and equivalents: $210MQ2'24, Long-term debt: $1.2BQ2'24Q3'24, Cash and equivalents: $238MQ3'24, Long-term debt: $997MQ4'24, Cash and equivalents: $238MQ4'24, Long-term debt: $697MQ4'24Q1'25, Cash and equivalents: $426MQ1'25, Long-term debt: $668MQ2'25, Cash and equivalents: $522MQ2'25, Long-term debt: $663MQ2'25Q3'25, Cash and equivalents: $933MQ3'25, Long-term debt: $663MQ4'25, Cash and equivalents: $1.2BQ4'25, Long-term debt: $658MQ4'25Q1'26, Cash and equivalents: $1.4BQ1'26, Long-term debt: $409MQ2'26, Cash and equivalents: $1.4BQ2'26, Long-term debt: $404MQ2'26Q3'26, Cash and equivalents: $1.7BQ3'26, Long-term debt: $404MQ4'26, Cash and equivalents: $1.5BQ4'26, Long-term debt: $399MQ4'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q4 FY2026 filed August 13, 2026.

ResMed Inc. income statement, quarterly
Millions of dollarsQ4 FY2026ended Jun 30, 2026filed Aug 13, 2026Q3 FY2026ended Mar 31, 2026filed May 1, 2026Q2 FY2026ended Dec 31, 2025filed Jan 30, 2026Q1 FY2026ended Sep 30, 2025filed Oct 31, 2025Q4 FY2025ended Jun 30, 2025filed Aug 8, 2025Q3 FY2025ended Mar 31, 2025filed Apr 24, 2025Q2 FY2025ended Dec 31, 2024filed Jan 31, 2025Q1 FY2025ended Sep 30, 2024filed Oct 25, 2024YoYQ4 FY2026vs Q4 FY2025
Revenue1,4641,4311,4231,3361,3481,2921,2821,225+8.6%
Cost of revenue602540544515528525531507+14.1%
Gross profit861891879821820766751717+5.0%
Research and development10694918786848180+22.3%
Selling, general and administrative296286278259267245242239+10.9%
Operating income449500492447455426417387−1.3%
Other income (expense)253404(9)1(4)+624.5%
Pretax income474502496447458418418383+3.5%
Income tax911041049878537472+15.8%
Net income383399393349380365345311+1.0%
Diluted EPS ($)—2.742.682.37—2.482.342.11—
Diluted shares (millions)—146146147—147147148—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q4 FY2026 filed August 13, 2026.

ResMed Inc. balance sheet, quarterly
Millions of dollarsQ4 FY2026ended Jun 30, 2026filed Aug 13, 2026Q3 FY2026ended Mar 31, 2026filed May 1, 2026Q2 FY2026ended Dec 31, 2025filed Jan 30, 2026Q1 FY2026ended Sep 30, 2025filed Oct 31, 2025Q4 FY2025ended Jun 30, 2025filed Aug 8, 2025Q3 FY2025ended Mar 31, 2025filed Apr 24, 2025Q2 FY2025ended Dec 31, 2024filed Jan 31, 2025Q1 FY2025ended Sep 30, 2024filed Oct 25, 2024YoYQ4 FY2026vs Q4 FY2025
Cash and equivalents1,4691,6611,4171,3841,209933522426+21.5%
Short-term investments—————————
Total current assets4,3254,0643,8193,6263,5063,2082,8362,641+23.4%
Total assets8,9668,7848,5038,3088,1747,5677,1417,222+9.7%
Total current liabilities1,3951,3511,2481,2561,019941852904+36.9%
Long-term debt399404404409658663663668−39.3%
Total liabilities2,3812,2922,1822,1872,2072,0211,8882,027+7.9%
Stockholders’ equity6,5856,4926,3216,1215,9685,5465,2535,195+10.3%
Shares outstanding (millions)144145146146146147147147—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q4 FY2026 filed August 13, 2026.

ResMed Inc. cash flow statement, quarterly
Millions of dollarsQ4 FY2026ended Jun 30, 2026filed Aug 13, 2026Q3 FY2026ended Mar 31, 2026filed May 1, 2026Q2 FY2026ended Dec 31, 2025filed Jan 30, 2026Q1 FY2026ended Sep 30, 2025filed Oct 31, 2025Q4 FY2025ended Jun 30, 2025filed Aug 8, 2025Q3 FY2025ended Mar 31, 2025filed Apr 24, 2025Q2 FY2025ended Dec 31, 2024filed Jan 31, 2025Q1 FY2025ended Sep 30, 2024filed Oct 25, 2024YoYQ4 FY2026vs Q4 FY2025
Operating cash flow455554340457539579309326−15.6%
Capital expenditures5134294331212118+67.2%
Free cash flow (CFO − capex)404520311414508558288308−20.6%
Depreciation and amortization4559504864444645−29.6%
Share repurchases200175175150100757550+100.0%
Dividends paid8787888878787878+12.2%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2026 filed August 13, 2026.

Income statement

ResMed Inc. income statement, annual
Millions of dollarsFY2026ended Jun 30, 2026filed Aug 13, 2026FY2025ended Jun 30, 2025filed Aug 8, 2025FY2024ended Jun 30, 2024filed Aug 9, 2024FY2023ended Jun 30, 2023filed Aug 11, 2023FY2022ended Jun 30, 2022filed Aug 12, 2022FY2021ended Jun 30, 2021filed Aug 17, 2021FY2020ended Jun 30, 2020filed Aug 13, 2020FY2019ended Jun 30, 2019filed Aug 8, 2019FY2018ended Jun 30, 2018filed Aug 17, 2018FY2017ended Jun 30, 2017filed Aug 4, 2017FY2016ended Jun 30, 2016filed Aug 5, 2016FY2015ended Jun 30, 2015filed Aug 7, 2015FY2014ended Jun 30, 2014filed Aug 8, 2014FY2013ended Jun 30, 2013filed Aug 13, 2013FY2012ended Jun 30, 2012filed Aug 14, 2012FY2011ended Jun 30, 2011filed Aug 17, 2011FY2010ended Jun 30, 2010filed Nov 3, 2010FY2009ended Jun 30, 2009filed Nov 3, 2010
Revenue5,6535,1464,6854,2233,5783,1972,9572,6072,3402,0671,8391,6791,5551,5141,3691,2431,092921
Cost of revenue2,2022,0912,0301,8671,5541,3581,2391,1131,005865————————
Gross profit3,4523,0552,6552,3562,0241,8391,7181,4941,3351,2021,0661,011990941821741655554
Research and development378331308288254225202181155144119115118120110927563
Selling, general and administrative1,120993917874738670677645600554488479450431403372329290
Operating income1,8871,6851,3201,1321,000904810579542426429409405355294267240190
Other income (expense)33(8)(55)(30)(40)(20)(77)(60)(21)(7)1127263038372011
Pretax income1,9191,6781,2651,102960884733519521419440436431385332304261202
Income tax396277244204181409111114206768783867877777155
Net income1,5231,4011,021898779475622405316342352353345307255227190146
Diluted EPS ($)10.439.516.926.095.303.244.272.802.192.402.492.472.392.101.711.441.230.95
Diluted shares (millions)146147148147147146146144144142142143144146149157155154

Balance sheet

ResMed Inc. balance sheet, annual
Millions of dollarsFY2026ended Jun 30, 2026filed Aug 13, 2026FY2025ended Jun 30, 2025filed Aug 8, 2025FY2024ended Jun 30, 2024filed Aug 9, 2024FY2023ended Jun 30, 2023filed Aug 11, 2023FY2022ended Jun 30, 2022filed Aug 12, 2022FY2021ended Jun 30, 2021filed Aug 17, 2021FY2020ended Jun 30, 2020filed Aug 13, 2020FY2019ended Jun 30, 2019filed Aug 8, 2019FY2018ended Jun 30, 2018filed Aug 17, 2018FY2017ended Jun 30, 2017filed Aug 4, 2017FY2016ended Jun 30, 2016filed Aug 5, 2016FY2015ended Jun 30, 2015filed Aug 7, 2015FY2014ended Jun 30, 2014filed Aug 8, 2014FY2013ended Jun 30, 2013filed Aug 13, 2013FY2012ended Jun 30, 2012filed Aug 14, 2012FY2011ended Jun 30, 2011filed Aug 17, 2011FY2010ended Jun 30, 2010filed Nov 3, 2010FY2009ended Jun 30, 2009filed Nov 3, 2010
Cash and equivalents1,4691,209238228274295463147189822731717906876810735489416
Short-term investments——————————————————
Total current assets4,3253,5062,3582,3681,9311,5751,5231,1451,0661,6441,4201,4081,5561,4491,3611,292985—
Total assets8,9668,1746,8726,7525,0964,7284,5874,1083,0643,4683,2572,1822,3612,2112,1382,0691,626—
Total current liabilities1,3951,019911759689912603556511360638266270574253209313—
Long-term debt3996586971,4317656431,1641,2592701,07987330130112511000—
Total liabilities2,3812,2072,0082,6221,7351,8422,0902,0351,0051,5081,562594603600530338339—
Stockholders’ equity6,5855,9684,8644,1303,3612,8862,4972,0722,0591,9601,6951,5871,7581,6111,6081,731——
Shares outstanding (millions)144146147147146146145144143142141141140142142152151—

Cash flow statement

ResMed Inc. cash flow statement, annual
Millions of dollarsFY2026ended Jun 30, 2026filed Aug 13, 2026FY2025ended Jun 30, 2025filed Aug 8, 2025FY2024ended Jun 30, 2024filed Aug 9, 2024FY2023ended Jun 30, 2023filed Aug 11, 2023FY2022ended Jun 30, 2022filed Aug 12, 2022FY2021ended Jun 30, 2021filed Aug 17, 2021FY2020ended Jun 30, 2020filed Aug 13, 2020FY2019ended Jun 30, 2019filed Aug 8, 2019FY2018ended Jun 30, 2018filed Aug 17, 2018FY2017ended Jun 30, 2017filed Aug 4, 2017FY2016ended Jun 30, 2016filed Aug 5, 2016FY2015ended Jun 30, 2015filed Aug 7, 2015FY2014ended Jun 30, 2014filed Aug 8, 2014FY2013ended Jun 30, 2013filed Aug 13, 2013FY2012ended Jun 30, 2012filed Aug 14, 2012FY2011ended Jun 30, 2011filed Aug 17, 2011FY2010ended Jun 30, 2010filed Nov 3, 2010FY2009ended Jun 30, 2009filed Nov 3, 2010
Operating cash flow1,8061,7521,401693351737802459505414548——403383283188239
Capital expenditures15690991201351039569636259637364476757110
Free cash flow (CFO − capex)1,6501,6621,302574216634707390442352489——339336217131129
Depreciation and amortization2011981771651601571551511201128773737886716254
Share repurchases70030015000——2354—10216020218639316313169
Dividends paid35031128225824522722521219918616815714297————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$5M
6 sales by 3 insiders; officers and directors $5M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$22M
32 sales by 5 insiders; officers and directors $22M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 23, 2026Rider Michael JGlobal General Counselopen-market sale10b5-1400$255.00$102K12,318Oct 26, 2026
Oct 7, 2026Farrell Michael J.Chairman and CEO, Directoroption exercise4,991$146.34$730K484,794Oct 8, 2026
Oct 7, 2026Farrell Michael J.Chairman and CEO, Directoropen-market sale10b5-14,991$226.33$1M479,803Oct 8, 2026
Sep 8, 2026Farrell Michael J.Chairman and CEO, Directoroption exercise4,991$146.34$730K471,247Sep 10, 2026
Sep 8, 2026Farrell Michael J.Chairman and CEO, Directoropen-market sale10b5-14,991$222.44$1M466,256Sep 10, 2026
Sep 2, 2026Farrell Peter CDirectoropen-market sale10b5-1970$234.73$228K51,803Sep 4, 2026
Aug 14, 2026Leong JustinChief Product Officeraward6,461$0.00—35,489Oct 1, 2026
Aug 14, 2026Rider Michael JGlobal General Counselaward3,230$0.00—12,718Oct 1, 2026
Aug 14, 2026Farrell Michael J.Chairman and CEO, Directoraward13,547$0.00—479,803Oct 1, 2026
Aug 14, 2026Bloomer AaronChief Financial Officeraward9,072$0.00—9,072Oct 1, 2026
Aug 7, 2026Farrell Michael J.Chairman and CEO, Directoroption exercise4,991$146.34$730K471,247Aug 11, 2026
Aug 7, 2026Farrell Michael J.Chairman and CEO, Directoropen-market sale10b5-14,991$205.69$1M466,256Aug 11, 2026
Aug 5, 2026Farrell Peter CDirectoropen-market sale10b5-18,000$225.00$2M52,773Aug 6, 2026
Jul 7, 2026Farrell Michael J.Chairman and CEO, Directoroption exercise4,991$146.34$730K471,214Jul 9, 2026
Jul 7, 2026Farrell Michael J.Chairman and CEO, Directoropen-market sale10b5-14,991$218.55$1M466,223Jul 9, 2026
Jun 8, 2026Farrell Michael J.Chairman and CEO, Directoroption exercise4,991$146.34$730K471,214Jun 9, 2026
Jun 8, 2026Farrell Michael J.Chairman and CEO, Directoropen-market sale10b5-14,991$193.96$968K466,256Jun 9, 2026
Jun 1, 2026Rider Michael JGlobal General Counseltax withholding269$190.57$51K9,488Jun 3, 2026
May 7, 2026Farrell Michael J.Chairman and CEO, Directoroption exercise4,991$146.34$730K471,214May 11, 2026
May 7, 2026Farrell Michael J.Chairman and CEO, Directoropen-market sale10b5-14,991$207.82$1M466,223May 11, 2026
Apr 7, 2026Farrell Michael J.Chairman and CEO, Directoroption exercise4,991$146.34$730K471,214Apr 9, 2026
Apr 7, 2026Farrell Michael J.Chairman and CEO, Directoropen-market sale10b5-14,991$225.50$1M466,223Apr 9, 2026
Apr 1, 2026Sandercock BrettChief Financial Officeropen-market sale10b5-11,000$224.31$224K83,495Apr 3, 2026
Apr 1, 2026Farrell Peter CDirectoropen-market sale10b5-12,000$225.00$450K60,773Apr 2, 2026
Mar 9, 2026Farrell Michael J.Chairman and CEO, Directoroption exercise4,991$146.34$730K471,214Mar 11, 2026

Full insider history for ResMed Inc., or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 6; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
ResMed Inc., CIK 943819 on EDGAR
Extract generated
October 6, 2026
Withheld
none
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: not filed
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends

The data

The statements on this page as files, generated October 6, 2026.

JSON file
/data/financials/RMD.json